Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Abou-Alfa Discusses Ongoing Studies of Immunotherapy in HCC

Ghassan K. Abou-Alfa, MD
Published: Saturday, Jan 21, 2017


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma (HCC).
 
The field of immunotherapy in HCC is moving extremely fast, Abou-Alfa says. There is quite a bit of evidence showing the expression of PD-1 and PD-L1 expression, as well as other markers for checkpoint inhibitors.
 
CheckMate-040, looking at nivolumab (Opdivo) in patients with HCC, showed a continued response rate of 22%. Based on this data, CheckMate-459, a study of nivolumab versus sorafenib (Nexavar), is now ongoing in the first-line setting.
 
Along that same line, the argument of whether to use checkpoint inhibitors in HCC is still unclear. For that purpose, a study of second-line pembrolizumab versus best supportive care is currently ongoing.
 
In addition, there is data suggesting that the combination of checkpoint inhibitors may be valuable in this disease, Abou-Alfa says.
 

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma (HCC).
 
The field of immunotherapy in HCC is moving extremely fast, Abou-Alfa says. There is quite a bit of evidence showing the expression of PD-1 and PD-L1 expression, as well as other markers for checkpoint inhibitors.
 
CheckMate-040, looking at nivolumab (Opdivo) in patients with HCC, showed a continued response rate of 22%. Based on this data, CheckMate-459, a study of nivolumab versus sorafenib (Nexavar), is now ongoing in the first-line setting.
 
Along that same line, the argument of whether to use checkpoint inhibitors in HCC is still unclear. For that purpose, a study of second-line pembrolizumab versus best supportive care is currently ongoing.
 
In addition, there is data suggesting that the combination of checkpoint inhibitors may be valuable in this disease, Abou-Alfa says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x